The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -5.38 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -1.52 — flag raised, worth a closer lookWatch
- Earnings quality 82/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Travere Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Net product sales$410.5M
- FILSPARI$322.0M
- Tiopronin products$88.5M
- License and collaboration revenue$80.3M
- Market Access Milestone$40.0M
Leadership changes
From Travere Therapeutics, Inc.'s own filings, the day they're filed.
- William Rote · Chief Research Officer · departureeff. 2027-02-17
Latest filings
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-21
- 8-K · Company announcement2026-05-11
- 8-K · Company announcement2026-05-04
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Travere Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when Travere Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.